Anthony Tighe

555 Wilmslow Road
Manchester, ENG M204GJ, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

A clinical-stage oncology compound selectively targets drug-resistant cancers.

A clinical-stage oncology compound selectively targets drug-resistant cancers.

Journal: bioRxiv : the preprint server for biology
Published: December 15, 2025

Targeting SUMOylation in ovarian cancer: Sensitivity, resistance, and the role of MYC.

Targeting SUMOylation in ovarian cancer: Sensitivity, resistance, and the role of MYC.

Journal: iScience
Published: November 29, 2024

Screening a living biobank identifies cabazitaxel as a strategy to combat acquired taxol resistance in high-grade serous ovarian cancer.

Screening a living biobank identifies cabazitaxel as a strategy to combat acquired taxol resistance in high-grade serous ovarian cancer.

Journal: Cell reports. Medicine
Published: October 25, 2024

Intrinsic PARG inhibitor sensitivity is mimicked by TIMELESS haploinsufficiency and rescued by nucleoside supplementation.

Intrinsic PARG inhibitor sensitivity is mimicked by TIMELESS haploinsufficiency and rescued by nucleoside supplementation.

Journal: NAR cancer
Published: February 28, 2024

Exploiting a living biobank to delineate mechanisms underlying disease-specific chromosome instability.

Exploiting a living biobank to delineate mechanisms underlying disease-specific chromosome instability.

Journal: Chromosome research : an international journal on the molecular, supramolecular and evolutionary aspects of chromosome biology
Published: April 25, 2023

Multiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitors.

Multiple-low-dose therapy: effective killing of high-grade serous ovarian cancer cells with ATR and CHK1 inhibitors.

Journal: NAR cancer
Published: May 19, 2022

Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models.

Replication catastrophe is responsible for intrinsic PAR glycohydrolase inhibitor-sensitivity in patient-derived ovarian cancer models.

Journal: Journal of experimental & clinical cancer research : CR
Published: August 17, 2021

Inhibitors of the Bub1 spindle assembly checkpoint kinase: synthesis of BAY-320 and comparison with 2OH-BNPP1.

Inhibitors of the Bub1 spindle assembly checkpoint kinase: synthesis of BAY-320 and comparison with 2OH-BNPP1.

Journal: Royal Society open science
Published: May 13, 2021

TP53 loss initiates chromosomal instability in fallopian tube epithelial cells.

TP53 loss initiates chromosomal instability in fallopian tube epithelial cells.

Journal: Disease models & mechanisms
Published: March 12, 2021

Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes.

Distinct transcriptional programs stratify ovarian cancer cell lines into the five major histological subtypes.

Journal: Genome medicine
Published: January 21, 2021

A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity.

A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity.

Journal: Nature communications
Published: November 21, 2018

DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors.

DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors.

Journal: Cancer cell
Published: September 20, 2018
Showing 1-12 of 18

Last Updated: 09/26/2026